真实世界中慢性髓性白血病患者酪氨酸激酶抑制剂停药状况分析:单中心经验
回顾性分析北京大学人民医院2013年1月至2016年8月非临床试验的662例CML-CP患者,中位随访26个月,187例(28.2%)曾中断TKI治疗≥2周,停药原因以血液学不良反应(57.8%)最常见,其次为非血液学不良反应(30.4%)和经济困难(25.1%);因血液学不良反应或经济困难停药与较低的TKI治疗反应率和较短的无进展生存相关。
要点
- 662例CML-CP患者中187例(28.2%)曾中断TKI治疗≥2周。
- 停药原因:血液学不良反应57.8%、非血液学不良反应30.4%、经济困难25.1%、其他7.0%。
- 因血液学不良反应或经济困难停药者完全细胞遗传学反应率、CMR率及4年无疾病进展生存率显著低于未停药者。
核心结论
- 真实世界中TKI治疗中停药的原因半数为TKI相关血液学不良反应,因非血液学不良反应和经济困难停药者各约占1/4。
- 因血液学不良反应和经济困难停药与不良的治疗结果相关。
- 中国CML患者的治疗现状距离停药标准尚有很大差距,目前谈无治疗缓解(TFR)为时过早。
研究设计与样本
- 回顾性分析2013年1月至2016年8月在北京大学人民医院就诊的非临床试验的CML-CP患者病例资料,共收集662例服用TKI的CML-CP患者。
主要发现
- TKI治疗后中位随访26(3~187)个月,187例(28.2%)患者曾中断TKI治疗≥2周。
- 停药原因包括血液学不良反应108例(57.8%)、非血液学不良反应57例(30.4%)、经济困难47例(25.1%)和其他13例(7.0%)。
- 多因素分析显示女性、年龄≥40岁、无共存疾病、诊断距TKI治疗间隔≥6个月、曾更换TKI和来自外院与因血液学不良反应停药显著相关;女性和来自外院与因非血液学不良反应停药显著相关;曾更换TKI、目前服用仿制品和来自外院与因经济困难而停药显著相关。
- 因血液学、非血液学不良反应和经济困难停药的患者完全细胞遗传学反应率显著低于未停药患者(P值分别为<0.001、0.025、<0.001),因血液学不良反应和经济困难停药的患者完全分子学反应(CMR)率显著低于未停药患者(P值均<0.001)。
- 因血液学不良反应和经济困难停药的患者4年无疾病进展生存率显著低于未停药患者(P值分别为<0.001、0.023);7例持续获得CMR后停药的患者中5例在停药后3(2~32)个月BCR-ABL融合基因转阳;来自外院的39例持续为BCR-ABL阴性的患者中21例(53.8%)北京大学人民医院检测BCR-ABL为阳性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore status of tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia (CML) in the chronic phase (CP) in the real world, to analyze causes, factors and outcomes associated with TKI discontinuation and the possibility of pursuit treatment-free remission (TFR) in China. Methods: From January 2013 to August 2016, data of CML-CP patients in Peking University People's Hospital which were not enrolled in clinical trials were retrospectively collected and analyzed. Results: Data of 662 CML-CP patients were collected. With a median follow-up after TKI-therapy of 26 months (range, 3-187 months) , 187 patients (28.2%) experienced TKI cessation of at least 2 weeks. Causes of TKI discontinuation included hematologic adverse events 57.8% (n=108) , non-hematologic adverse events 30.4% (n=57) , financial burden 25.1% (n=47) , and others 7.0% (n= 13) . Multivariate analyses showed female, ≥40 years, no co-morbidity, and interval from diagnosis to TKI initiation ≥6 months, TKI switch and patients from other hospitals were factors associated with TKI discontinuation because of hematologic adverse effects. Female and patients from other hospitals were factors associated with TKI discontinuation because of non-hematologic adverse effect. TKI switch, generic TKI used and patients from other hospitals were factors associated with TKI discontinuation because of financial toxicity. Patients TKI discontinuation because of hematologic, non-hematologic or financial toxicity achieved a lower complete cytogenetic response or complete molecular response (CMR) than those with uninterrupted TKI-therapy. Patients with TKI discontinuation because of hematologic or financial toxicity had a shorter progression-free survival than those with uninterrupted TKI-therapy. 5 of 7 patients who obtained sustained CMR and discontinued TKI-therapy experienced disease recurrence with a median duration of 3 months (range, 2-32 months) . In 39 patients from other hospitals who aimed to confirm their optimal response of sustained CMR in Peking University People's Hospital, 21 (53.8%) were BCR-ABL positive. Conclusion: In the real world in China, half of CML-CP patients who discontinued TKI-therapy were incurred to TKI-related hematologic adverse effect, and both a quarter of them, TKI-related non-hematologic toxicities and financial toxicity, respectively. Discontinued TKI-therapy due to hematologic adverse events or financial toxicity was associated with lower TKI-therapy response rates. Nowadays, based on the Chinese situation, it is too early to talk about TFR. 目的: 探讨真实世界中慢性髓性白血病慢性期(CML-CP)患者的酪氨酸激酶抑制剂(TKI)停药状况,分析停药原因及相关因素,以及目前中国CML患者追求无治疗缓解(TFR)的可能性。 方法: 回顾性分析2013年1月至2016年8月在北京大学人民医院就诊的非临床试验的CML-CP患者病例资料。 结果: 共收集662例服用TKI的CML-CP患者的临床资料,TKI治疗后中位随访时间为26(3~187)个月,187例(28.2%)患者曾中断TKI治疗≥2周,原因包括:血液学不良反应108例(57.8%)、非血液学不良反应57例(30.4%)、经济困难47例(25.1%)和其他13例(7.0%)。多因素分析显示,女性、年龄≥40岁、无共存疾病、诊断距TKI治疗间隔≥6个月、曾更换TKI和来自外院与因血液学不良反应停药显著相关;女性和来自外院与因非血液学不良反应停药显著相关;曾更换TKI、目前服用仿制品和来自外院与因经济困难而停药显著相关。因血液学、非血液学不良反应和经济困难停药的患者完全细胞遗传学反应率显著低于未停药患者(P值分别为<0.001、0.025、<0.001),因血液学不良反应和经济困难停药的患者完全分子学反应(CMR)率显著低于未停药患者(P值均<0.001)。因血液学不良反应和经济困难停药的患者4年无疾病进展生存率显著低于未停药患者(P值分别为<0.001、0.023)。7例持续获得CMR后停药的患者中,5例在停药后3(2~32)个月BCR-ABL融合基因转阳。来自外院的39例持续为BCR-ABL阴性的患者中,21例(53.8%)北京大学人民医院检测BCR-ABL为阳性。 结论: 真实世界中,TKI治疗中停药的原因半数为TKI相关血液学不良反应,因非血液学不良反应和经济困难停药者各约占1/4。因血液学不良反应和经济困难停药与不良的治疗结果相关。中国CML患者的治疗现状,距离停药标准尚有很大差距。.
引用
- Yu L, Qin YZ, Jiang Q, et al. [Analysis on tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia in the real world: experience from single center]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29081191. doi:10.3760/cma.j.issn.0253-2727.2017.09.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。